Tasquinimod: Phase III started

Active Biotech disclosed in its 1Q14 earnings that in February partner Ipsen began a double-blind, placebo-controlled, Asian Phase III trial to evaluate 0.25, 0.5 and 1 mg oral tasquinimod once daily ...